Determinants of brain natriuretic peptide gene expression and secretion in acute cardiac allograft rejection

Current Opinion in Cardiology

Volumn 22, Issue 2, 2007, Pages 146-150

  De Bold, Adolfo J ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Atrial natriuretic factor; Brain natriuretic peptide; Heart transplantation; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE GRAFT REJECTION; CARDIAC GRAFT REJECTION; CORRELATION ANALYSIS; GENE EXPRESSION; GRAFT RECIPIENT; HEART GRAFT; HEART MUSCLE CELL; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; IN VITRO STUDY; MYOCARDITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW;

ACUTE DISEASE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; NATRIURETIC PEPTIDE, BRAIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846880445     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328028fd7e     Document Type: Review

References (13)

1. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005; 16:469-477.
2. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 2005; 108:23-36.
3. Masters RG, Davies RA, Veinot JP, et al. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999; 100:287-291.
4. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by proinflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004; 36:505-513.
5. Ogawa T, Veinot JP, Davies RA, et al. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 2005; 24:1046-1054. This reference describes in detail neurohumoral changes in heart transplant recipients in relation to posttransplantation time, hemodynamic variables, and ISHLT biopsy grades.
6. Duquesnoy RJ, Demetris AJ. Immunopathology of cardiac transplant rejection. Curr Opin Cardiol 1995; 10:193-206.
7. Azzawi M, Grant SD, Hasleton PS, et al. TNF alpha mRNA and protein in cardiac transplant biopsies: comparison with serum TNF alpha levels. Cardiovasc Res 1996; 32:551-556.
8. Grant SC, Lamb WR, Brooks NH, et al. Serum cytokines in human heart transplant recipients: is there a relationship to rejection? Transplantation 1996; 62:480-491.
9. Hirata Y, Matsumoto A, Aoyagi T, et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001; 51:585-591.
10. Hervás I, Almenar L, Perez-Pastor JL, et al. Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determinations and biopsy grading of rejection. Nucl Med Commun 2003; 24:925-931.
11. Mehra MR, Uber PA, Potluri S, et al. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 2004; 94:454-458.
12. Park MH, Uber PA, Scott RL, Mehra MR. B-type natriuretic peptide in heart transplantation: an important marker of allograft performance. Heart Fail Rev 2003; 8:359-363.
13. Mehra MR, Uber PA, Walther D, et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker. Circulation 2006; 114:I21-I26.